Three former FDA commissioners are calling on FDA, CMS and Congress to work with stakeholders to increase the use of real-world evidence (RWE) and real-world data (RWD) in order to improve the evidence base for new drugs and biologics; refine regulatory decisions by FDA; and promote value-based payment models to make health care more affordable. In a letter at the start of a 54-page report on RWE published by the Bipartisan Policy Center (BPC), former FDA chiefs Robert Califf, Andrew...